Loading…
← CockpitCompetitor Analysis › 688085.SS Shanghai Sanyou Medical Co. Ltd. Class AOpen in the cockpit ↗

Shanghai Sanyou Medical Co. Ltd. Class A688085.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum strong 71
Mkt cap
$692M
US dollars, full cap
Free float
59%
of shares outstanding
$/day
$7.94M
20-day average traded
Fwd P/E
50.0×
forward earnings
ROIC−WACC
-3.5 pp
WACC 6.7%
Hurdle
+22 pp
Req g minus delivered
Next earnings
160 days
27 Apr 2027
Close · CNYCN¥12.66
1D-4.0%
1W-3.7%
1M-1.0%
3M-8.3%
6M-22.9%
YTD-22.7%
1Y-29.8%
ATR %4.6%
52w lowhigh41.6% off high

What Shanghai Sanyou Medical does

Employees: 539

Shanghai Sanyou Medical at a glance

Size Shanghai Sanyou Medical (688085.SS) is a China Health Care company (Medical Specialties) with a market value of $692M, the 2919th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.66 on 18 Nov 2026.

Performance Over six months the shares fell 22.9%, against -12.4% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue grew 15.4% over the last twelve months (peer median +14.1%); the operating margin is 4.2% (peer median 13.7%).

Valuation It trades at 50.0× forward earnings against a peer median of 21.7× (3rd most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 29% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +22 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 3.5 points below its cost of capital (6.7% WACC).

Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).

Relative performance

70809010021 May 202621 Aug 202618 Nov 2026Peer median 89688085.SS 77
Six months, rebased to 100: Shanghai Sanyou Medical against the median of its 20 peers (local-currency closes).

Shanghai Sanyou Medical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥591MCN¥539MCN¥450MCN¥457MCN¥642M
Revenue growth—+20%-1%-29%—
Gross profitCN¥476MCN¥373MCN¥292MCN¥349MCN¥566M
EBITDAn/aCN¥110MCN¥67.3MCN¥156MCN¥207M
Net incomeCN¥48.5MCN¥63.1MCN¥11.5MCN¥95.6MCN¥191M
Free cash flowCN¥31.6MCN¥41.5M-CN¥23.7MCN¥243MCN¥26.7M
Capital expenditureCN¥40.7MCN¥28.9MCN¥37.4MCN¥25.9MCN¥138M
Total debtCN¥72.4MCN¥56.0MCN¥54.0MCN¥4.99MCN¥5.39M

Quarterly statements and history in the cockpit →

Shanghai Sanyou Medical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%688389301234491000DCTH15017575002876688410300622301122300326SNTQDEL688179301367600855INMD603108300453002950688085.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shanghai Sanyou Medical is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%0×200×688389DCTH15017575002876688410300622301122300326QDEL603108688085.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shanghai Sanyou Medical is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%688389301234DCTH15017575688410300622300326SNT688179INMD603108688085.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shanghai Sanyou Medical is the large dot.

Shanghai Sanyou Medical competitors and peer comparison

How Shanghai Sanyou Medical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shanghai Sanyou Medical against its 20 peers (data as of 18 Nov 2026)
Measure688085.SSPeer medianRank in peer set
1-month return-1.0%-8.9%6th highest of 21
6-month return-22.9%-12.4%7th lowest of 21
Distance from 52-week high-41.6%-35.5%9th lowest of 21
Revenue growth (TTM)+15.4%+14.1%10th highest of 21
Operating margin4.2%13.7%7th lowest of 21
Forward P/E50.0×21.7×3rd most expensive of 17
Growth the price implies (Req g, 7 yrs)29.0%6.6%3rd most demanding of 16
Growth delivered (Del g)+6.8%+14.2%5th lowest of 16
Hurdle (Req g minus delivered)+22.2 pp-12.4 pp2nd most demanding of 16
ROIC minus cost of capital-3.5 pp+3.8 pp6th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shanghai Sanyou Medical 688085.SSChina$692M-23%+15%4%50.0×29.0%+6.8%
Shenzhen Lifotronic Technology 688389.SSChina$692M-14%+14%13%29.9×11.6%+13.3%
Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZChina$697M+148%-14%3%n/a31.8%-0.6%
Livsmed 491000.KSSouth Korea$687M-47%+89%-77%n/an/an/a
Delcath Systems DCTHUnited States$685M+75%+38%5%358.9×33.4%+120.2%
Shanghai INT Medical Instruments 1501.HKHong Kong$700M-25%+35%21%15.9×-3.3%+23.5%
Japan Lifeline 7575.TJapan$703M+34%+6%19%14.5×-9.5%+2.9%
Shenzhen Sunnypol Optoelectornics 002876.SZChina$680M-9%+29%5%39.0×10.1%+14.2%
SWS Hemodialysis Care 688410.SSChina$706M-11%+31%19%23.5×16.2%+25.9%
Doctorglasses Chain 300622.SZChina$710M-22%+6%14%22.8×-3.4%+15.7%
Caina Technology 301122.SZChina$721M+36%+61%0%55.4×n/an/a
Shanghai Kinetic Medical 300326.SZChina$662M-10%-28%17%26.0×6.6%-1.9%
Synektik SNT.WAPoland$662M+10%+32%24%13.8×0.2%+47.5%
QuidelOrtho QDELUnited States$657M-20%-5%-2%10.7×n/an/a
Shanghai Aladdin Biochemical Technology 688179.SSChina$736M-37%+39%24%27.4×17.1%+24.2%
BMC Medical 301367.SZChina$737M-17%+37%17%18.7×-1.5%+15.6%
Beijing Aerospace Changfeng 600855.SSChina$738M-44%-10%-19%n/an/an/a
InMode INMDUnited States$741M-8%+2%18%9.8×-10.8%+12.4%
Shanghai Runda Medical Technology 603108.SSChina$744M-36%-12%-2%20.5×20.3%-0.2%
Jiang Xi Sanxin Medtec 300453.SZChina$744M-3%+12%18%16.2×-1.9%+11.8%
Allmed Medical Products 002950.SZChina$747M-32%+14%8%n/an/an/a

Questions

Which companies are Shanghai Sanyou Medical's closest peers?
The cockpit's peer set: Shenzhen Lifotronic Technology (688389.SS), Anhui Hongyu Wuzhou Medical Manufacturer (301234.SZ), Livsmed (491000.KS), Delcath Systems (DCTH), Shanghai INT Medical Instruments (1501.HK), Japan Lifeline (7575.T), Shenzhen Sunnypol Optoelectornics (002876.SZ), SWS Hemodialysis Care (688410.SS).
Is Shanghai Sanyou Medical expensive compared with its peers?
On forward p/e it trades at 50.0× against a peer median of 21.7×, 3rd most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 29% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +22 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Shanghai Sanyou Medical stock performed?
Over six months to 18 Nov 2026 the shares returned -22.9% against -12.4% for the median peer; over one year -29.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.